Supporting Your Journey
Every Step of the Way.

Cohesive strategic consultancy and operational capability
in Regulatory, Drug Safety and Quality.

Descriptive text for the image
Guiding You Through
Pharmaceutical Regulation.

Regulatory expertise supporting you every step of the way,
from CTA/IND to product approval and beyond.

Descriptive text for the image
Navigating You Through EU
and US GxP Compliance.

Our deep expertise makes GxP compliance plain sailing.

Descriptive text for the image
Your Product Launch
is Our Mission.

Providing you with a trusted platform for your
product launch and ongoing compliance.

Descriptive text for the image

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

We are deliberately moving towards establishing ourselves, not just as a Drug Safety service provider, but as a strategic partner that can add optimal value to our clients, now and over the long term. This allows us to move away from being purely transactional, towards being a true partner from development to market, across all aspects of Drug Safety.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Arriello Boston
Arriello Boston

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

We are deliberately moving towards establishing ourselves, not just as a Drug Safety service provider, but as a strategic partner that can add optimal value to our clients, now and over the long term. This allows us to move away from being purely transactional, towards being a true partner from development to market, across all aspects of Drug Safety.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Arriello Boston
Arriello Boston

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

We are deliberately moving towards establishing ourselves, not just as a Drug Safety service provider, but as a strategic partner that can add optimal value to our clients, now and over the long term. This allows us to move away from being purely transactional, towards being a true partner from development to market, across all aspects of Drug Safety.

EudraVigilance (European Union Drug Regulating Authorities Pharmacovigilance) is a data processing network and management system operated by European Medicines Agency (EMA) on behalf of the European Union (EU) medicines regulatory network.

Its scope covers drugs which are in development and existing marketed products and is supported by the eXtended EudraVigilance Medicinal Product Dictionary (xEVMPD) containing details of all the development or licensed products within the EEA. 

Marketing Authorization Applicants (MAAs), Sponsors and Marketing Authorization Holders (MAHs) must be registered in the system and fully maintain a range of specific key data points.

Sponsors and MAHs can manage and submit ICSRs and SUSARs through EudraVigilance during clinical trials, the authorization period, or via data submission (art 57/ xEVMPD). The system also supports the detection and monitoring of safety signals, safety data analysis, and reporting through the EudraVigilance Data Analysis System (EVDAS) interface.

EudraVigilance (European Union Drug Regulating Authorities Pharmacovigilance) is a data processing network and management system operated by European Medicines Agency (EMA) on behalf of the European Union (EU) medicines regulatory network.

Its scope covers drugs which are in development and existing marketed products and is supported by the eXtended EudraVigilance Medicinal Product Dictionary (xEVMPD) containing details of all the development or licensed products within the EEA. 

Marketing Authorization Applicants (MAAs), Sponsors and Marketing Authorization Holders (MAHs) must be registered in the system and fully maintain a range of specific key data points.

Sponsors and MAHs can manage and submit ICSRs and SUSARs through EudraVigilance during clinical trials, the authorization period, or via data submission (art 57/ xEVMPD). The system also supports the detection and monitoring of safety signals, safety data analysis, and reporting through the EudraVigilance Data Analysis System (EVDAS) interface.

EudraVigilance (European Union Drug Regulating Authorities Pharmacovigilance) is a data processing network and management system operated by European Medicines Agency (EMA) on behalf of the European Union (EU) medicines regulatory network.

Its scope covers drugs which are in development and existing marketed products and is supported by the eXtended EudraVigilance Medicinal Product Dictionary (xEVMPD) containing details of all the development or licensed products within the EEA. 

Marketing Authorization Applicants (MAAs), Sponsors and Marketing Authorization Holders (MAHs) must be registered in the system and fully maintain a range of specific key data points.

Sponsors and MAHs can manage and submit ICSRs and SUSARs through EudraVigilance during clinical trials, the authorization period, or via data submission (art 57/ xEVMPD). The system also supports the detection and monitoring of safety signals, safety data analysis, and reporting through the EudraVigilance Data Analysis System (EVDAS) interface.

Without content padding

Hello

Hello

Hello

Hello

With content padding

Hello

Hello

Hello

Hello

Below are 3 new layouts

630

630

310

605

605

310

400

400

400

310